title: Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab.
authors.affiliation: Unit of Medicine and Clinical Immunology, Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Via Olgettina 60-20132 Milano, Italy. lorenzo.dagna@unisr.it
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Dagna
authors.forename: Angelo
authors.initials: A
authors.lastname: Corti
authors.forename: Silvia
authors.initials: S
authors.lastname: Langheim
authors.forename: Barbara
authors.initials: B
authors.lastname: Guglielmi
authors.forename: Francesco
authors.initials: F
authors.lastname: De Cobelli
authors.forename: Claudio
authors.initials: C
authors.lastname: Doglioni
authors.forename: Gabriele
authors.initials: G
authors.lastname: Fragasso
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Sabbadini
authors.forename: Marina
authors.initials: M
authors.lastname: Ferrarini
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D054413:Chemokine CCL11 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D031249:Erdheim-Chester Disease / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D000911:Antibodies, Monoclonal; D054413:Chemokine CCL11; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab